Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Graham Corporation enters the week before its November 6 earnings with short interest at a one-month high, an analyst target cut landing on the same day the stock fell 4.5%, and options traders positioned more bullishly than at almost any point in the past year.
Short interest has climbed 20% over the past month to 8.5% of the free float, reaching roughly 931,000 shares borrowed as of October 7. That rebuilding has been steady and deliberate rather than episodic. The borrow market, however, offers no amplifying pressure: availability runs at 635%, meaning roughly six shares are available to lend for every one currently borrowed. Cost to borrow is a negligible 0.48%. Nothing in the lending market suggests short sellers face any squeeze risk heading into the print.
Options positioning tells a strikingly different story. The put/call ratio has dropped to 0.17, nearly two standard deviations below its 20-day average of 0.22, placing it among the lowest defensive readings of the past year (the 52-week low is 0.12). Call open interest dominates the options book by a wide margin. That skew points to a market that is, on balance, positioned for the stock to recover rather than fall further, even as the share price has slipped 4% over the past month to $84.34.
The most immediate piece of Street news is the target cut from Oppenheimer this morning. Christopher Glynn, who initiated coverage in March and has been constructive throughout, lowered his price target from $130 to $115 while keeping his Outperform rating. JP Morgan added GHM to its coverage last week with an Overweight and a $120 target, the first time the firm has formally covered the name. Both targets sit well above the current price, implying 36% to 50% upside from current levels on the analyst consensus mean of $128.60, and the consensus rating remains a buy. The forward EPS growth factor ranks in the 85th percentile of the ORTEX universe, and analyst recommendation divergence scores in the 98th percentile, meaning the Street is almost uniformly positive relative to peers. Valuation is less comfortable: the trailing PE has compressed to roughly 39x on recent price weakness, though the EV/EBITDA of 21.9x has eased about 1.4 turns over the past month.
The institutional register adds texture to the ownership picture. First Trust Advisors added its entire position of 545,000 shares, or roughly 4.6% of the company, in the period ending September 30. BlackRock added 124,000 shares in the same period. T. Rowe Price, meanwhile, built a position of 616,000 shares, disclosed in August. Three separate 5% or near-5% holders growing simultaneously is notable for a company of this size. Brandes Investment Partners remains the largest holder at 9.2% but has been trimming, down from 11.3% at its prior disclosure. The Vanguard Group filed a 13G/A in March showing its stake had dropped to zero from 6.1%. No 13D activist is on the register.
The earnings history shows two very different reactions to the most recent prints. The August 25 quarterly report produced a 5.5% one-day drop and a 14% five-day loss. The prior print, on August 6, went the other direction, gaining 6.9% on the day and holding that gain over the following week. The next report is due November 6, roughly four weeks away.
What to watch: whether the options skew toward calls holds through the earnings approach, and whether the steady month-long rebuild in short interest pauses or accelerates as the November 6 date draws closer.
See the live data behind this article on ORTEX.
Open GHM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
